Miraculins detects protein biomarker in diagn
Miraculins detects protein biomarker in diagnostic
2006-10-11 09:30 ET - News Release
Mr. Christopher Moreau reports
MIRACULINS ANNOUNCES SUCCESSFUL ELISA TEST DEVELOPMENT
Miraculins Inc. has successfully detected the primary protein biomarker from its prostate cancer diagnostic, using an ELISA-based immunoassay.
"This is a very important step for the company," said Dr. Jim Charlton, president of Miraculins. "While we use mass spectrometry as our main tool of discovery, it is not a readily available or accepted diagnostic tool in most clinical laboratories. The development of immunoassays for our biomarkers is a critical step in preparation for marketing the final diagnostic test."
The colorimetric-based ELISA test that was used by the Miraculins's research team was also able to produce results in a sample subset consistent with the diagnostic results observed when using mass spectrometry for detection. The successful measurement of the biomarker using an immunoassay marks the first time that Miraculins has used an alternative diagnostic method in the verification of its research.
"Miraculins now plans to develop a more sensitive and complex ELISA test under contract with an outside manufacturer. This will move the company that much closer to having a developed test ready for regulatory approval," added Dr. Charlton.
We seek Safe Harbor.
Top